SYSTEMIC LUPUS ERYTHEMATOSUS

This study looks back at medical records to compare how well two existing drugs (telitacicept and belimumab) control lupus symptoms and how safe they are. Researchers will analyze data from 180 adults with moderate-to-severe lupus who were already taking one of these medications.…

This study is testing whether an oral medication called deucravacitinib can better control symptoms of active, moderate-to-severe lupus compared to a placebo. It involves 516 adults who will take the pill alongside their current lupus medications. The main goal is to see if it re…

This study is testing whether a weekly injection called anifrolumab can help control disease activity in adults with moderate-to-severe lupus who are already on standard treatments. About 360 participants will receive either the drug or a placebo for one year to see if it reduces…

This is an early safety study testing a single dose of an experimental cell therapy called SC291. It is for adults with severe forms of lupus or a blood vessel disease called ANCA-associated vasculitis that have not improved with at least two prior treatments. The goal is to see …

This early-stage study aimed to test the safety and initial effects of a single infusion of CB-010, a new type of cell therapy modified with CRISPR gene-editing, in adults with severe lupus that hasn't responded to standard treatments. The trial was designed to last about two yea…

This study is testing if adding the drug sirolimus to standard lupus treatment can better control the disease in adults who still have active symptoms. About 146 participants will receive either sirolimus or a placebo pill for 24 weeks, followed by an extension period where every…

This is an early-stage study testing a new personalized cell therapy called KITE-363 for people with severe autoimmune diseases that haven't improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells, which …

This study is testing a new type of cell therapy for people with severe lupus or scleroderma that hasn't responded to standard treatments. Doctors are giving patients a single infusion of specially engineered immune cells designed to target and reduce harmful B cells. The main go…

This study is testing whether adding an investigational drug called obinutuzumab to standard lupus therapy is better at controlling the disease than standard therapy alone. It involves about 300 adults with active, antibody-positive lupus. The main goal is to see if the drug help…

This study is testing whether adding a monthly injection called ianalumab to standard lupus treatment helps control the disease better than standard treatment alone. Researchers are enrolling 288 people with active systemic lupus erythematosus to see if the drug reduces disease f…

This was a large, late-stage study designed to test whether an investigational drug called telitacicept could better control disease activity in people with moderate-to-severe lupus compared to a placebo. The drug works by targeting parts of the immune system thought to drive the…

This study is testing a version of an existing lupus drug, belimumab, given as a shot under the skin (subcutaneous) in children aged 5 to 17. The main goals are to see if the drug reaches safe and effective levels in children's bodies and to monitor for side effects. Participants…

This early-stage study is testing a new cell therapy called CNTY-101 in people with severe autoimmune diseases like lupus, lupus nephritis, and scleroderma that have not improved with other treatments. The main goals are to find a safe dose and see if the therapy helps control th…

This large, late-stage study is testing whether an oral medication called deucravacitinib can better control active, moderate-to-severe lupus compared to a placebo. It involves over 500 participants who will take the pill alongside their standard lupus treatments. The main goal i…

This study continues testing an experimental lupus medication called dapirolizumab pegol to check its long-term safety and side effects. It involves 760 people with systemic lupus erythematosus who previously participated in related studies. The main goal is to monitor patients f…

This early-stage study is testing a new treatment called YTB323, a type of CAR-T cell therapy, for people with severe lupus that hasn't responded to other strong medications. The main goals are to see if the treatment is safe and if it can reduce lupus disease activity. Researche…

This study is testing whether a new antibody drug called MIL62 can help control the symptoms and disease activity of systemic lupus erythematosus (SLE). The trial will compare MIL62 against a placebo in 120 adults with active lupus over 76 weeks. Researchers will measure whether …

This early-stage study is testing the safety and initial effectiveness of a therapy called CAR-T for people with severe, treatment-resistant lupus. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells that drive the disease. The goal is…

This large, late-stage study is testing whether adding a new injectable drug called ianalumab to standard lupus care can better control the disease. About 436 people with active lupus will receive either the real drug or a placebo shot monthly or quarterly for over a year. The ma…

This study is testing whether gentle, low-frequency electromagnetic waves can help stabilize the immune system and reduce painful flare-ups in people with autoimmune diseases like lupus, rheumatoid arthritis, and multiple sclerosis. About 120 participants will receive either real…

This study follows 551 people with systemic lupus erythematosus (SLE) who are starting treatment with the drug anifrolumab in their regular doctor's offices. The goal is to see how well the drug controls lupus symptoms and improves quality of life over up to five years in real-wo…

This early-stage study is testing the safety of a new two-part cell therapy (SYNCAR-001 + STK-009) in adults with severe forms of lupus or scleroderma that haven't responded to other treatments. The therapy involves collecting and modifying a patient's own immune cells (CAR-T cel…

This study is testing whether a daily oral pill called GLPG3667 can safely reduce disease activity in adults with active systemic lupus erythematosus (SLE). About 180 participants will take either the study drug or a placebo for 48 weeks while continuing their standard lupus medi…

This early-stage study is testing the safety and initial effects of a therapy called RD06-04, a type of CAR-T cell injection, in adults with active autoimmune diseases like lupus, scleroderma, and vasculitis. The therapy involves collecting a patient's own immune cells, modifying…

This study is testing if a new, single auto-injector pen delivers the same amount of the drug ianalumab into the body as two separate pre-filled syringes. It involves 155 adults with rheumatoid arthritis, lupus, or Sjögren's disease. The main goal is to see if the drug levels in …

This study is a long-term follow-up for people with lupus who finished a previous 24-week trial of an experimental oral drug called enpatoran. It aims to see how safe and effective the drug is over a much longer period. The study includes about 379 participants with different for…

This study is checking if the Shingrix shingles vaccine is safe and works well for people with autoimmune rheumatic diseases like lupus or rheumatoid arthritis. These patients are at high risk for shingles but are often on medications that weaken the immune system. Researchers ar…

This study is testing if a specific type of blood pressure medication (lisinopril) can improve memory and concentration problems often experienced by people with lupus. Researchers will compare it to a different blood pressure drug (benazepril) in about 36 adults with stable lupu…

This study aims to find better ways to identify which people with lupus are most likely to develop heart disease. Researchers will follow 500 adult lupus patients, measuring specific substances in their blood and using ultrasound to track artery health over time. The goal is to d…

This study is testing a training program for doctors to improve pregnancy planning and contraception care for women with lupus. Researchers are adapting a program that worked at Duke University to see if it fits well at the University of Chicago Medical Center, which serves many …

This study aimed to gather information about pregnancy in women with rare autoimmune diseases like lupus and rheumatoid arthritis. Researchers planned to follow these pregnancies to understand complications and how medications affect both mother and baby. The goal was to use this…

This is the first time a new drug candidate for lupus is being given to people. The main goal is to check if it is safe and how the body processes it in healthy volunteers. The study is currently suspended and is not testing if the drug helps treat lupus symptoms.